Clinical trial NCT01558219: Second-line Chemotherapy in Castration Resistant Prostate Cancer
Official title: Open, Single-arm, Multicenter, Phase II Trial Investigating the Safety of Biweekly Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With a Docetaxel-containing Regimen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Prostate Cancer
Keywords: Metastatic prostate cancer
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
Collaborators: name: Helsinki University Central Hospital
name: Turku University Hospital
name: Kuopio University Hospital
name: Seinajoki Central Hospital
First posted: 2012-03-20
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the safety of biweekly cabazitaxel for the treatment of metastatic castration resistant prostate cancer (mCRPC) patients previously treated with docetaxel containing regimen. The primary endpoint is safety. Secondary endpoints include time to treatment failure, response rate, overall survival and quality of life.

Detailed description: The objective of this study is to explore new, biweekly schedule of cabazitaxel in metastatic castration resistant prostate cancer patients. A previous study has shown that the biweekly administration of docetaxel in 1st line setting of mCRPC is better tolerated than docetaxel administered every three weeks. Also, the efficacy of biweekly docetaxel was better than three-weekly docetaxel and biweekly dosing presented a significant overall survival benefit (ASCO 2011, Kellokumpu-Lehtinen et al. As the occurrence of neutropenia in the TROPIC trial was rather high, the hypothesis is to reduce the incidence of severe adverse events by administrating cabazitaxel more frequently, yet maintaining the same dose intensity as in every three weeks´ dosing schedule.

This study is designed to evaluate the safety of biweekly cabazitaxel for the treatment of 60 patients with metastatic castration resistant prostate cancer (mCRPC) patients previously treated with docetaxel containing regimen.

Eligibility criteria: Inclusion Criteria:

* Metastatic castration resistant prostate cancer
* Disease progression during or after docetaxel-containing regimen for mCRPC
* Surgical or medical castration
* WHO performance status \< 2
* Age \> 18 years
* Adequate bone marrow, liver and renal functions:

Hematology:

* neutrophils \> 1.5 x 109/ l
* hemoglobin \> 100 g/l
* platelets \> 100 x 109/l

Hepatic and renal functions:

* total bilirubin \<1 x ULN
* ALAT and ASAT \< 2.5 x ULN, alkaline phosphate \<6 x ULN.In the presence of extensive bone disease, alkaline phosphate \> 6 x ULN is accepted
* creatinine \< 1.5 x ULN (ie NCI CTC-AE grade \< 1)

Exclusion Criteria:

* Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment
* Prior therapy with radioisotopes
* Other malignant disease (except superficial non-melanoma skin cancer) within the past 5 years
* Serious liver disease
* History of severe hypersensitivity reaction (grade \> 3) to polysorbate 80 containing drugs
* Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who already are on these treatments)
* Other serious illness or medical condition:
* Serious cardiac disease; ischemic or thromboembolic cardiac disease, pulmonary emboli, cardiac infarction within 12 months
* Active infection
* Active peptic ulcer, uncontrolled diabetes mellitus or other contraindications for the use of corticosteroids
* Auto-immune disease (lupus, scleroderma, rheumatoid polyarthritis)
* Active grade \> 2 polyneuropathy

Primary outcomes:
measure: Safety and tolerabilty
timeFrame: every 2 weeks
Secondary outcomes:
measure: Response rate
timeFrame: PSA every 6 week, tumor assesment every 12 week
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: Tampere University Hospital
Study officials:
affiliation: Tampere University Hospital
name: Pirkko-Liisa I kellokumpu-Lehtinen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: